By Dr Mark Alastair Boyd

Journal articles

Zhou J; Li PCK; Kumarasamy N; Boyd MA; Chen YMA; Sirisanthana T; Sungkanuparph S; Oka S; Tau G; Phanuphak P; Saphonn V; Zhang FJ; Omar SFS; Lee CKC; Ditangco R; Merati TP; Lim PL; Choi JY; Law MG; Pujari S, 2010, 'Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD)', HIV Medicine, 11, pp. 31 - 39

Carey DL; Amin J; Boyd MA; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials', Journal of Antimicrobial Chemotherapy, 65, pp. 1878 - 1888

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current Opinion in HIV and AIDS, 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.0b013e328329fc8d

Boyd M, 2009, 'Clinical research in low- And middle-income countries', Virtual Mentor, 11, pp. 511 - 515, http://dx.doi.org/10.1001/virtualmentor.2009.11.7.jdsc1-0907

Boyd MA; Emery S; Cooper DA, 2009, 'Antiretroviral roll-out: the problem of second-line therapy', Lancet, 374, pp. 185 - 186

Mcintyre GJ; Yu Y; Tran A; Jaramillo AB; Arndt AJ; Millington ML; Boyd MP; Elliott FA; Shen SW; Murray JM; Applegate TL, 2009, 'Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success', Virology Journal, 6, pp. 184, http://www.virologyj.com/content/6/1/184

Byakwaga H; Zhou J; Petoumenos K; Law MG; Boyd MA; Emery S; Cooper DA; Mallon PW, 2009, 'Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy', HIV Medicine, 10, pp. 143 - 151

Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA, 2009, 'Evolution of CD4+T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression', AIDS Research and Human Retroviruses, 25, pp. 569 - 576

Boyd MA, 2009, 'Improvements in antiretroviral therapy outcomes over calendar time', Current opinion in HIV & AIDS, 4, pp. 194 - 199, http://dx.doi.org/10.1097/COH.013e328329fc8d

Colebunders R; French M; Oelrichs R; Boyd M, 2008, 'Editorial introductions', Current Opinion in HIV and AIDS, 3, pp. vii - viii, http://dx.doi.org/10.1097/COH.0b013e32830890a4

Oelrichs R; Boyd M, 2008, 'Evidence and policy in the globalized response to AIDS', Current Opinion in HIV and AIDS, 3, pp. 477 - 480, http://dx.doi.org/10.1097/COH.0b013e328303ba0b

Boyd MA; Truman M; Holes G; Anderson JA; Dwyer DE; Carr AD, 2008, 'A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)', Antiviral Therapy, 13, pp. 449 - 453

Boyd MA; Byakwaga H, 2008, 'Considering the benefits of disease-specific interventions on overall public health', Lancet Infectious Diseases, 8, pp. 278 - 278

Boyd MA; Pett SL, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', Australian Prescriber, 31, pp. 66 - 69

Mackowiak PA; Boyd MA; Menon P; Graves S; Gordon DL, 2007, 'A Febrile Illness with Generalized Papular Rash Involving the Palms and Soles', Clinical Infectious Diseases, 44, pp. 755 - 756, http://dx.doi.org/10.1086/511651

Boyd MA; Menon P; Graves S; Gordon DL, 2007, 'A febrile illness with generalized papular rash involving the palms and soles', Clinical Infectious Diseases, 44, pp. 704 - 756, http://dx.doi.org/10.1086/511637

Boyd MA; Hedger S, 2007, 'An unusual cause of severe metabolic acidosis [5]', Medical Journal of Australia, 186, pp. 158, http://dx.doi.org/10.5694/j.1326-5377.2007.tb00846.x

Snelling T; Ossowicz C; Boyd M, 2007, 'Case report: Co-infections in an HIV-infected man from Malawi', American Journal of Tropical Medicine and Hygiene, 76, pp. 180 - 181, http://dx.doi.org/10.4269/ajtmh.2007.76.180

Boyd MA; Truman M; Hales GP; Anderson JS; Dwyer DE; Carr AD, 2007, 'A randomized study to evaluate injection site reactions (ISR) using three different mechanisms for delivery of enfuvirtide (ENF): a 27-gauge needle, a 31-gauge needle and a needle-free device', Antiviral Therapy, 12, pp. L57 - L57

Kerr SJ; Duncombe CJ; Avihingsanon A; Ananworanich J; Boyd MA; Sopa B; Chuenyam T; Cooper DA; Lange JM; Phanuphak P; Ruxrungtham K, 2007, 'Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.', Journal of the International Association of Physicians in AIDS Care, 6, pp. 36 - 46

Boyd MA, 2007, 'Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?', Expert Opinion on Pharmacotherapy, 8, pp. 957 - 964

Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG, 2007, 'Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment', HIV Medicine, 8, pp. 46 - 54

Autar R; Boyd MA; Wit F; Ruxrungtham K; Sankote J; Lange JM; Cooper DA; Phanuphak P; Burger DM; Reiss P, 2007, 'Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen', Antiviral Therapy, 12, pp. 1265 - 1271

Boyd MA; Cooper DA, 2007, 'Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research', AIDS, 21, pp. S55 - S63

Cooper DA; Cahn PE; Lewin S; Kaldor JM; McClure C; Kort R; Boyd MA, 2007, 'The Sydney Declaration: a call to scale up research', Lancet, 370, pp. 7 - 8

Boyd M; Clezy K; Lindley R; Pearce R, 2006, 'Pandemic influenza: Clinical issues', Medical Journal of Australia, 185, pp. S44 - S47, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00706.x

Kong A; Koukourou A; Boyd M; Crowe G, 2006, 'Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis', Journal of Clinical Neuroscience, 13, pp. 955 - 958, http://dx.doi.org/10.1016/j.jocn.2005.11.039

Boyd M; Reiss P, 2006, 'Erratum: The long-term effects of antiretroviral therapy: A review (Journal of HIV Therapy 11, 2 (28))', Journal of HIV Therapy, 11

Boyd M; Rogers W, 2006, 'Industry and bioethics: What price the relationship? [3]', Plos Medicine, 3, pp. 0933, http://dx.doi.org/10.1371/journal.pmed.0030281

Boyd M; Reiss P, 2006, 'The long-term consequences of antiretroviral therapy: A review', Journal of HIV Therapy, 11, pp. 26 - 35

Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange JM; Cooper DA; Phanuphak P, 2006, 'Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).', Antiviral Therapy, 11, pp. 223 - 232

Boyd MA; Carr AD; Ruxrungtham K; Srasuebkul P; Bien D; Law MG; Wangsuphachart S; Krisanachinda A; Lerdlum S; Lange J; Phanuphak P; Cooper DA; Reiss P, 2006, 'Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to Ritonavir-boosted Indinavir and Efavirenz', Journal of Infectious Diseases, 194, pp. 642 - 650

Boyd MA; Burger D; Phanuphak P; Cooper DA, 2006, 'Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis', AIDS, 20, pp. 1083 - 1085

Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie P; Uchaipichat V; Stek M; Lange JM; Phanuphak P; Cooper DA; Udomuksorn W; Miners JO, 2006, 'Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir', Pharmacogenetics and Genomics, 16, pp. 321 - 329

Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger D, 2006, 'The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity', Journal of Antimicrobial Chemotherapy, 57, pp. 1161 - 1167

Boyd MA; Dixit N; Siangphoe U; Buss N; Salgo M; Lange J; Phanuphak P; Cooper DA; Perelson A; Ruxrungtham K, 2006, 'Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012)', Journal of Infectious Diseases, 194, pp. 1319 - 1322

Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P, 2005, 'Indinavir/ritonavir 800/100mg bid and efavirenz 600mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009', HIV Medicine, 6, pp. 410 - 420

Macpherson JL; Boyd MP; Arndt AJ; Todd AV; Ganning GC; Ely JA; Elliott F; Knop A; Raponi M; Murray JM; Gerlach W; Sun L; Penny R; Symonds GP; Carr AD; Cooper DA, 2005, 'Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients', Journal of Gene Medicine, 7, pp. 552 - 564

Boyd MA; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange JM; Cooper DA; Phanuphak P; Ruxrungtham K, 2005, 'Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients', Antiviral Therapy, 10, pp. 301 - 307

Ananworanich J; Cheunyam T; Teeratakulpisarn S; Boyd MA; Ruxrungtham K; Lange PJ; Cooper PD; Phanuphak PP, 2004, 'Creation of a drug fund for post-clinical trial access to antiretrovirals', Lancet, 364, pp. 101 - 102, http://dx.doi.org/10.1016/S0140-6736(04)16596-3

Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA; Dore GJ, 2004, 'Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort', AIDS, 18, pp. 1169 - 1177

Ruxrungtham K; Boyd MA; Bellibas S; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH, 2004, 'Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients', Journal of Clinical Pharmacology, 44, pp. 793 - 802

Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH, 2003, 'Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide', Journal of Clinical Pharmacology, 43, pp. 1382 - 1391

Burger D; Boyd M; Duncombe CJ; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper DA; Lange JM; Phanuphak P; Reiss P, 2003, 'Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients', Journal of Antimicrobial Chemotherapy, 51, pp. 1231 - 1238

Boyd MA; Aarnoutse RE; Ruxrungtham K; Stek M; van Heeswijk RP; Lange JM; Cooper DA; Phanuphak P; Burger DM, 2003, 'Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects', Journal of Acquired Immune Deficiency Syndrome, 34, pp. 134 - 139

Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA, 2003, 'Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001', AIDS, 17, pp. 2191 - 2199

Conference Papers

Lau A; Kong F; Fairley C; Templeton D; Amin J; Phillips S; Law M; Chen M; Bradshaw C; Donovan B; McNulty A; Boyd M; Timms P; Chow E; Regan D; Khaw C; Lewis D; Kaldor J; Ratnayake M; Carvalho N; Hocking J, 2021, 'O11.2 Treatment efficacy of 1g azithromycin versus 100mg doxycycline bi-daily for seven days for asymptomatic rectal Chlamydia trachomatis', in STI treatment, BMJ Publishing Group Ltd, pp. A40.2 - A40, presented at Abstracts for the STI & HIV World Congress, July 14–17 2021, http://dx.doi.org/10.1136/sextrans-2021-sti.111

Gartner C; Boyd M; Bonevski B; Gilks C; Borland R; Courtney R; Cobiac L; McRobbie H; Baker P; Mueller J, 2018, 'CESSATION AND RELAPSE PREVENTION TRIAL: VAPORISED NICOTINE PRODUCTS FOR PEOPLE ON OPIATE SUBSTITUTION THERAPY, OR WHO ARE LIVING WITH HEPATITIS C OR HIV', in DRUG AND ALCOHOL REVIEW, WILEY, pp. S6 - S6, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449495000013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Khaw C; Raw L; Zablotska-Manos I; Boyd M, 2018, 'Chemsex: prevalence, characteristics and associated risk profiles of men who have sex with men in South Australia. A cross-sectional cohort study', in HIV MEDICINE, WILEY, pp. S46 - S46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000430174700122&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Holt SG; Gracey DM; Mudge DW; Irish AB; Sevastos J; Walker RG; Baer RA; Levy MT; Boyd MA, 2014, 'RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY', in NEPHROLOGY, WILEY-BLACKWELL, pp. 72 - 72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339715700206&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page